47 results on '"Lee, Jung-Yun"'
Search Results
2. TP003/#1557 An open label, single arm, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16 or 18 positive cervical cancer (DURBAC)
3. PO010/#673 A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
4. TP016/#1542 A multicenter study of niraparib as maintenance therapy in BRCA wild-type, newly diagnosed advanced ovarian cancer (Polo trial)
5. PR061/#869 A retrospective study on the comparison of responsiveness of each chemotherapy for recurrent ovarian cancer after maintenance treatment with PARP inhibitors
6. TP007/#1383 A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)
7. EP015/#747 Prognostic impact of CD73 expression in epithelial ovarian cancer
8. EP264/#775 Genomic alteration before and after progression on first exposure to parp inhibitor (PARPi) among ovarian cancer patients
9. PO007LBA/#1550 Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study
10. PR003/#357 Peripheral PD-1+regulatory T cells for predicting treatment response to parp inhibitor maintenance in patients with epithelial ovarian cancer
11. EP139/#824 Would preoperative molecular profiling of P53 mutation and mismatch repair deficiency be useful as markers to predict the extent of surgery in early-stage endometrial cancer?
12. 710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
13. EP267/#913 Monitoring of minimal residual disease with circulating tumor DNA in patients with epithelial ovarian cancer on long-term PARP inhibitor maintenance therapy
14. EP266/#907 Relationship of immune-related diabetes mellitus with efficacy of immune checkpoint inhibitors in patients with gynecologic cancers
15. TP011/#1536 A double-blind placebo-controlled phase III chemo-immunotherapy (Paclitaxel-carboplatin-oregovomab [PCO]) vs chemotherapy (Paclitaxel-carboplatin-placebo [PCP]) in patients with newly diagnosed, advanced epithelial ovarian cancer (EOC): FLORA-5/GOG-3035 study
16. PR008/#805 Efficacy and safety of BVAC-C in HPV type 16 or 18 positive cervical carcinoma who failed 1st platinum based chemotherapy: a phase I/IIA study
17. PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)
18. EP269/#163 CD8 and vimentin was associated with overall survival in patients with ovarian cancer treated with intraperitoneal chemotherapy
19. 729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
20. EP272/#891 Impact of clinical trial participation on the survival of patients with newly diagnosed advanced-stage ovarian cancer
21. EP166/#912 Prevalence of paraaortic lymph node metastasis in presumed clinical stage II endometrial cancer
22. #783 Total laparoscopic radical parametrectomy with pelvic lymphadenectomy
23. #800 Could the preoperative status of P53 mutation and mismatch repair deficiency be useful as predictive biomarker for the extent of surgery in early-stage endometrial cancer patients?
24. #1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial
25. #1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial
26. EP069/#855 Comprehensive profiling of cervix cancer patients using tumor next-generation sequencing (NGS) and immunohistochemistry (IHC)
27. O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial
28. EP256/#931 Re-validation of chemotherapy response score (CRS) as a prognostic factor in ovarian cancer: the effect of bevacizumab and hipec on survival
29. EP255/#721 Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: single-institution cohort study
30. EP072/#875 Patient-derived organoids as a preclinical platform for precision medicine in patients with cervical cancer
31. EP105/#578 Added value of sentinel lymph node biopsy in patients with negative lymph node on triple pre-operative images
32. EP125/#679 Do mmr and p53 status in chemo-naïve endometrial cancer patients influence response to chemotherapy?
33. SF028/#694 Laparoscopic left common iliac vein injury and repair
34. EP016/#807 Dynamic changes of peripheral regulatory t cells during parp inhibitor maintenance therapy in patients with ovarian cancer
35. TP002/#1563 An open label, single arm, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16 or 18 positive recurrent cervical cancer
36. TP029/#1459 Prospective multi-institutional phase III trial of standard of care therapy with or without sterotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC, KGOG 3064/KROG 2204)
37. EP242/#861 Human epidermal growth factor receptor-2 (HER2) receptor expression and its dynamic change in ovarian cancer patients
38. TP027/#586 A multicenter study of niraparib maintenance therapy in BRCA wild-type, newly diagnosed advanced ovarian cancer: polo trial
39. EP252/#515 Prediction of surgical outcomes of interval debulking surgery (IDS) using in advanced ovarian cancer: a novel scoring system using post-neoadjuvant chemotherapy (NAC) computed tomography (CT)
40. EP152/#348 Propensity score-matched comparison of perioperative outcomes using da vinci XI and SP surgical system in endometrial cancer surgical staging
41. 8/#234 Immune properties of tumor-infiltrating lymphocytes in ovarian clear cell carcinoma relative to ovarian high-grade serous carcinoma
42. LB002/#1545 Late-breaking abstract presentation: comparative effectiveness of HIPEC following interval cytoreductive surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy: multicenter, prospective, cohort study (KGOG 3042)
43. TP032/#1532 Oregovomab and non-platinum single agent chemotherapy in parp inhibitor-resistant ovarian cancer patients not candidate for platinum retreatment: a multi-cohort phase II study (KGOG 3065/APGOT-OV6)
44. SF003/#669 Robotic-assisted radical vaginal trachelectomy
45. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 + TILs based on BRCA1/2 mutation status in epithelial ovarian cancers.
46. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.
47. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 + CD8 T cells from primary and metastatic sites of epithelial ovarian cancers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.